Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Tissue Procurement For Hematolymphoid Conditions

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.

OBJECTIVES:

• Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies.
• Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies.
• Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research.
• Address medical and legal issues, and protect participant and patient privacy and confidentiality.
• Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers.
• Support young investigators to obtain pilot data for grant funding.

OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.

DISEASE CHARACTERISTICS:

• Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:

  • Acute myeloid leukemia
  • Acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Chronic lymphoid leukemia
  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Myelodysplastic syndromes
  • Myeloproliferative disorders
  • Multiple myeloma
  • Waldenstrom macroglobulinemia
  • Aplastic anemia
  • Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage

• Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified